A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Baldi, A Malaise, Jacques Mourad, Michel [UCL] Squifflet, Jean-Paul [UCL]

Document type	Article de périodique (Journal article) – Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
Publication date	2000
Journal information	"Transplantation proceedings" - Vol. 32, no. 2, p. 429-31 (2000)
Peer reviewed	yes
issn	0041-1345
Publication status	Publié
Affiliation	UCL
MESH Subject	Actuarial Analysis ; Antilymphocyte Serum - adverse effects - therapeutic use ; Disease-Free Survival ; Follow-Up Studies ; Graft Rejection - drug therapy ; Humans ; Immunosuppressive Agents - adverse effects - therapeutic use ; Kidney Transplantation - immunology - mortality - physiology ; Muromonab-CD3 - adverse effects - therapeutic use ; Prospective Studies ; Survival Rate ; Time Factors
Links	https://doi.org/10.1016/S0041-1345(00)00838-1[DOI] http://www.ncbi.nlm.nih.gov/pubmed/10715467[PubMed] http://hdl.handle.net/2078.1/24110[Handle]

Bibliographic reference	Baldi, A ; Malaise, Jacques ; Mourad, Michel ; Squifflet, Jean-Paul. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.. In: Transplantation proceedings, Vol. 32, no. 2, p. 429-31 (2000)
Permanent URL	http://hdl.handle.net/2078.1/24110